Oryzon Genomics (ORY) Q4 2025 earnings summary

Executive summary

• FY2025 net loss was €2.605m, down from €3.577m in re-expressed FY2024; operating loss widened to €5.710m from €4.423m.

• Year-end cash was €28.354m ($33.3m), supported by €36.133m in net financing cash flows.

• Advanced iadademstat in oncology/hematology and vafidemstat in CNS disorders across ongoing and planned clinical trials.

• Appointed Dr. Rolando Gutierrez-Esteinou as Chief Medical Officer for CNS.

Financial highlights

• Work performed for own assets was €10.934m, up from €7.359m; other operating income was €716k, versus €134k.

• Personnel expenses increased to €4.524m from €3.447m, and other operating expenses rose to €12.418m from €8.098m.

• Financial income was €713k versus €204k; financial expenses fell to €608k from €1.227m. A €2.993m tax credit reduced the €5.598m loss before tax to a €2.605m net loss.

• Dollar results reported R&D expenses of $14.8m, G&A expenses of $5.6m and net loss of $6.7m for 2025; net loss per share was -$0.04.

• Total assets were €144.524m at year-end 2025, versus €109.846m a year earlier; equity was €117.848m versus €88.172m.

Clinical development

• Seven iadademstat trials were ongoing; reported data included 100% ORR and 90% strict CR in first-line AML, and 67% CCR at a selected dose in R/R FLT3+ AML.

• Vafidemstat trials in schizophrenia continued to expand, alongside preparation for a Phase II aggression trial in ASD.

• RESTORE enrolled its first two sickle cell disease cohorts; EMA approved a new Phase II trial in essential thrombocythemia.

• New trials were initiated in small cell lung cancer and essential thrombocythemia, extending development into non-malignant hematological disorders.

• New patents granted or pending in multiple jurisdictions strengthened IP protection for iadademstat and vafidemstat.